A phase III, randomized, double-blind, placebo-controlled trial evaluating clinical outcomes following percutaneous coronary intervention in patients treated with an abciximab bolus plus 12-hour infusion given with either standard-dose weight-adjusted heparin or low-dose weight-adjusted heparin
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2007
At a glance
- Drugs Abciximab; Heparin
- Indications Coronary artery disease; Coronary stent thrombosis
- Focus Therapeutic Use
- Sponsors Janssen Biotech
- 06 Apr 2007 Status changed from in progress to completed.
- 16 Nov 2006 New trial record.